I bought a block of Acadia in the $1's, lucky me.
2:15 PM ET, 11/25/2015
Leerink affirms Zogenix (Nasdaq: ZGNX) with an Outperform rating and $26 price target after the company announced the presentation of clinical and scientific posters, and the hosting of a scientific exhibit room at the 69th Annual American Epilepsy Society Meeting, which will take place in Philadelphia, PA, from December 4 - 8, 2015. Analyst Paul Matteis summarized: This morning 3 American Epilepsy Society (AES) abstracts became available, which put forth new data regarding the efficacy, cardiovascular safety and possible mechanism of low dose fenfluramine (ZX008) for the treatment of Dravet Syndrome. Encouragingly, an abstract that includes 7 additional patients treated with fenfluramine (since the publication of the Belgian 12-patient Dravet study) showed a 73% median convulsive seizure frequency reduction at 6 months relative to a 3-month baseline period. Moreover, all 7 patients, who were genotyped (SCN1A test) for Dravet syndrome, based on FDA/EMA clinical trial endpoints would be categorized as "responders", as each experienced a greater than a 50% reduction in seizure frequency. These data, along with another abstract that showed a lack of cardiovascular (CV) signal in the same 7 patients during a median of 22 months of treatment, add support to the clinical potential of ZX008 in Dravet ahead of phase III initiation this quarter.
Those are the new arrivals and the Longs know the story.
Are Analysts Bullish Inuvo Inc (NYSEMKT:INUV) After Last Week?
November 22, 2015
by Sally Goff
Out of 2 analysts covering Inuvo (NYSEMKT:INUV), 2 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Inuvo was the topic in 2 analyst reports since September 29, 2015 according to StockzIntelligence Inc. Below is a list of Inuvo Inc (NYSEMKT:INUV) latest ratings and price target changes.
29/09/2015 Broker: Roth Capital Rating: Buy New Target: $4.50 Initiate
29/09/2015 Broker: TH Capital Rating: Buy New Target: $4.50 Initiate
Maxim Introduces New Price Target For AEterna Zentaris Inc. (USA) (AEZS) On Back Of New Capital Structure
Jason Cohen, Editor — November 23, 2015
In a research report released today, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), while introducing a new price target of $11.00, after updating the model for the new capital structure and share count and adjusting assumptions for funding (capital raises).
Kolbert noted, “Management announced the clean-up of the company’s capital structure, with the majority of outstanding warrants (multiple traunches) now eliminated. With a reverse split now effective, the company has approximately 6.6M shares outstanding. We do not have the final numbers yet, but the overhang from the warrants has for the most part been eliminated.”
The analyst continued, “Last week, management announced that the first patient has been enrolled for the confirmatory Phase III clinical study to demonstrate the efficacy of Macrilen for adult growth hormone deficiency (AGHD). This is a big deal, as it means the trial is now running. We believe Macrilen is a viable therapeutic/ diagnostic that will be used in the AGHD marketplace and potentially in traumatic brain injury.”
All the 3 analysts polled by TipRanks rate Aeterna Zentaris stock a Buy. With a return potential of 887%, the stock’s consensus target price stands at $48.67.
I am expecting a 50% increase in the share price with an advance into the $20's during these last six weeks of 2015.
on November 10, 2015
Zogenix, Inc. (NASDAQ:ZGNX) has been given a 1.4 average broker rating according to Zacks Research. Zacks compiles research brokerage recommendations and places them into a simplified Buy/Sell scale. The scale rates stocks from 1 to 5 where 1 represents a Strong Buy and 5 a Strong Sell. Three months ago the firm had an average broker rating of 1.4.
Wall Street brokerages covering Zogenix, Inc. have also issued short and long term stock projections and earnings estimates. In the near-term Wall Street has a consensus price target of $26.5 for the next 12-months. The analysts with the most positive view of the shares has a target of $28. The most bearish research analyst has a conservative target of $23 on the stock.
News Watch International
Nov 12, 2015
Brokerage firm Leerink Swann Maintains its rating on Zogenix, Inc. – Common Stock(NASDAQ:ZGNX). As per the latest information, Leerink Swann Lowers the price target to $26.00 per share from a prior target of $27.00. The shares have been rated Outperform. The rating by Leerink Swann was issued on Nov 10, 2015.
Zogenix, Inc. (NASDAQ:ZGNX): The mean short term price target for Zogenix, Inc. (NASDAQ:ZGNX) has been established at $26.5 per share. The higher price target estimate is at $28 and the lower price target estimate is expected at $23 according to 4 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $2.38.
Several sellers took profit immediately near the open when the stock did not show upside continuation. Earnings miss by 10% of estimation yesterday resulting in an equaling 10% decline in the share price.
Analysts who follow the company hold the key to the future direction of the stock price as their estimates have held strong in the past. The current price targets are all $6.00, which has dictated the stock price trading in a bracketed range while hovering above and below that $6.00 bulls eye with consistency.
Investors will need to wait and see what their assessment after earnings response is, regarding their updated consensus on price targets. I am skeptic not a believer in the self-serving Motley Fool, Seeking Alpha and any other such nonsense from paying corrupt Long and/or Short clients of Yahoo Finance.
i recall your messages from the Zogenix message board. Pernix Therapeutics Holdings is an absolute gold mine at this price and I have struck the Mother Load.
For those who may be lurking, please take a few minutes and look at the 5 Year Chart. In my estimation this company stock is poised to make a run to $11 a share.
Enjoy the ride.